Baseline patient characteristics
| Variables | iAAA | rAAA | ||||||||
| n=837 | n=149 | |||||||||
| OAR | EVAR | P value | OAR | EVAR | P value | |||||
| n=593 | n=244 | n=110 | n=39 | |||||||
| Age, median (IQR) | 62.0 | (31.0–69.0) | 65.0 | (31.0–69.0) | <0.0001* | 59.0 | (53.0–59.0) | 62.0 | (59.0–67.0) | <0.0001* |
| Female gender, n (%) | 74 | 12.5% | 10 | 4.1% | <0.0001† | 12 | 10.9% | 3 | 7.7% | 0.76† |
| Hypertension, n (%) | 377 | 63.6% | 158 | 64.8% | 0.81† | 80 | 72.7% | 26 | 66.7% | 0.54† |
| Dyslipidemia, n (%) | 209 | 35.2% | 96 | 39.3% | 0.27† | 34 | 30.9% | 12 | 30.8% | 1.00† |
| Diabetes, n (%) | 87 | 14.7% | 33 | 13.5% | 0.74† | 18 | 16.4% | 6 | 15.4% | 1.00† |
| COPD, n (%) | 1 | 0.2% | 2 | 0.8% | 0.21† | 0 | 0.0% | 0 | 0.0% | –† |
| Cerebrovascular accident, n (%) | 38 | 6.4% | 8 | 3.3% | 0.09† | 4 | 3.6% | 2 | 5.1% | 0.65† |
| Kidney failure, n (%) | 12 | 2.0% | 4 | 1.6% | 1.00† | 12 | 10.9% | 3 | 7.7% | 0.76† |
| Atrial fibrillation, n (%) | 78 | 13.2% | 25 | 10.2% | 0.30† | 20 | 18.2% | 3 | 7.7% | 0.20† |
| Chronic heart failure, n (%) | 167 | 28.2% | 67 | 27.5% | 0.87† | 34 | 30.9% | 8 | 20.5% | 0.30† |
| Ischemic heart disease, n (%) | 147 | 24.8% | 59 | 24.2% | 0.93† | 16 | 14.5% | 5 | 12.8% | 1.00† |
| Coronary angiography, n (%) | 192 | 32.4% | 60 | 24.6% | 0.03† | 22 | 20.0% | 5 | 12.8% | 0.47† |
| Antiplatelet agent, n (%) | 260 | 43.8% | 113 | 46.3% | 0.54† | 32 | 29.1% | 11 | 28.2% | 1.00† |
| Oral anticoagulant, n (%) | 74 | 12.5% | 34 | 13.9% | 0.57† | 20 | 18.2% | 2 | 5.1% | 0.06† |
| Smoking, n (%) | 240 | 40.5% | 105 | 43.0% | 0.54† | 40 | 36.4% | 14 | 35.9% | 1.00† |
Categorical values are reported as total numbers (%) and continuous variables as medians (IQR).
*Wilcoxon rank-sum test.
†Fisher’s exact test.
COPD, Chronic Obstructive Pulmonary Disease ; EVAR, endovascular aortic repair; iAAA, intact abdominal aortic aneurysm; OAR, open aortic repair; rAAA, ruptured abdominal aortic aneurysm.